SYDNEY: Sigma Healthcare Limited announced that following almost eleven years as Managing Director & Chief Executive Officer, Mark Hooper has tendered his resignation.
In line with his contract, Mr Hooper has provided six months’ notice and anticipates leaving the Sigma business by the end of October 2021.
Mr Hooper commented, “Our transformation has progressed to plan and has returned Sigma to a position of strength, which creates the ideal opportunity to hand over the leadership to a new CEO.
The business is now in great shape, the financial performance is strong, and we have built a platform for sustainable growth over the next few years.”
Mr Hooper was appointed Managing Director & CEO in August 2010 and over the past decade has led the Sigma business through a major restructure following divestment of the Pharmaceutical division to Aspen Pharma in 2011, the acquisitions of CHS, MPS and MIA businesses between 2014 and 2018, transformation program “Project Pivot”, the renewal of Sigma’s national distribution centre network, and the imminent implementation of a new ERP system.
He was also Chair of the National Pharmaceutical Services Association (NPSA) from October 2015 to August 2020.